Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph phase_1
1
50%
Ph phase_4
1
50%

Phase Distribution

1

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution2 total trials
Phase 1Safety & dosage
1(50.0%)
Phase 4Post-market surveillance
1(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

2

all time

Status Distribution
Active(1)
Other(1)

Detailed Status

Not yet recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
0
Success Rate
N/A
Most Advanced
Phase 4

Trials by Phase

Phase 11 (50.0%)
Phase 41 (50.0%)

Trials by Status

not_yet_recruiting150%
unknown150%

Recent Activity

0 active trials
Showing 2 of 2
not_yet_recruitingphase_1

A Study to Evaluate the Biosimilarity of GLR1044 Injection and Dupilumab Injection (Dupixent®) in Healthy Adult Male Subjects

NCT07334496
unknownphase_4

Scientific Substantiation and Assessment of the Effectiveness of Pathogenetic Methods of Therapy for Congenital Ichthyosis in Children

NCT04996485

Clinical Trials (2)

Showing 2 of 2 trials
NCT07334496Phase 1

A Study to Evaluate the Biosimilarity of GLR1044 Injection and Dupilumab Injection (Dupixent®) in Healthy Adult Male Subjects

Not Yet Recruiting
NCT04996485Phase 4

Scientific Substantiation and Assessment of the Effectiveness of Pathogenetic Methods of Therapy for Congenital Ichthyosis in Children

Unknown

All 2 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
2